[Vaccination against human papillomaviridae. Expert correspondence no. 18 of 29 December 2006].
D000293:Adolescent; D000328:Adult; D002648:Child; D003430:Cross-Sectional Studies; D005060:Europe; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D007115:Immunization Schedule; D032541:Mass Vaccination; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000276:immunology; D015229:Sexually Transmitted Diseases, Viral / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D014481:United States; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18